Significant reduction of antibiotic use in the community after a nationwide campaign in France, 2002-2007.
Identifieur interne : 000491 ( Main/Corpus ); précédent : 000490; suivant : 000492Significant reduction of antibiotic use in the community after a nationwide campaign in France, 2002-2007.
Auteurs : Elifsu Sabuncu ; Julie David ; Claire Bernède-Bauduin ; Sophie Pépin ; Michel Leroy ; Pierre-Yves Boëlle ; Laurence Watier ; Didier GuillemotSource :
- PLoS medicine [ 1549-1676 ] ; 2009.
English descriptors
- KwdEn :
- Adolescent (MeSH), Age Distribution (MeSH), Anti-Bacterial Agents (therapeutic use), Child (MeSH), Drug Prescriptions (statistics & numerical data), Drug Resistance, Bacterial (MeSH), Drug Utilization (trends), France (MeSH), Health Policy (MeSH), Humans (MeSH), Influenza, Human (drug therapy), Practice Patterns, Physicians' (trends), Program Evaluation (MeSH), Public Health (MeSH).
- MESH :
- chemical , therapeutic use : Anti-Bacterial Agents.
- geographic : France.
- drug therapy : Influenza, Human.
- statistics & numerical data : Drug Prescriptions.
- trends : Drug Utilization, Practice Patterns, Physicians'.
- Adolescent, Age Distribution, Child, Drug Resistance, Bacterial, Health Policy, Humans, Program Evaluation, Public Health.
Abstract
BACKGROUND
Overuse of antibiotics is the main force driving the emergence and dissemination of bacterial resistance in the community. France consumes more antibiotics and has the highest rate of beta-lactam resistance in Streptococcus pneumoniae than any other European country. In 2001, the government initiated "Keep Antibiotics Working"; the program's main component was a campaign entitled "Les antibiotiques c'est pas automatique" ("Antibiotics are not automatic") launched in 2002. We report the evaluation of this campaign by analyzing the evolution of outpatient antibiotic use in France 2000-2007, according to therapeutic class and geographic and age-group patterns.
METHODS AND FINDINGS
This evaluation is based on 2000-2007 data, including 453,407,458 individual reimbursement data records and incidence of flu-like syndromes (FLSs). Data were obtained from the computerized French National Health Insurance database and provided by the French Sentinel Network. As compared to the preintervention period (2000-2002), the total number of antibiotic prescriptions per 100 inhabitants, adjusted for FLS frequency during the winter season, changed by -26.5% (95% confidence interval [CI] -33.5% to -19.6%) over 5 years. The decline occurred in all 22 regions of France and affected all antibiotic therapeutic classes except quinolones. The greatest decrease, -35.8% (95% CI -48.3% to -23.2%), was observed among young children aged 6-15 years. A significant change of -45% in the relationship between the incidence of flu-like syndromes and antibiotic prescriptions was observed.
CONCLUSIONS
The French national campaign was associated with a marked reduction of unnecessary antibiotic prescriptions, particularly in children. This study provides a useful method for assessing public-health strategies designed to reduce antibiotic use.
DOI: 10.1371/journal.pmed.1000084
PubMed: 19492093
PubMed Central: PMC2683932
Links to Exploration step
pubmed:19492093Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Significant reduction of antibiotic use in the community after a nationwide campaign in France, 2002-2007.</title><author><name sortKey="Sabuncu, Elifsu" sort="Sabuncu, Elifsu" uniqKey="Sabuncu E" first="Elifsu" last="Sabuncu">Elifsu Sabuncu</name><affiliation><nlm:affiliation>INSERM, U657, Paris, France.</nlm:affiliation></affiliation></author><author><name sortKey="David, Julie" sort="David, Julie" uniqKey="David J" first="Julie" last="David">Julie David</name></author><author><name sortKey="Bernede Bauduin, Claire" sort="Bernede Bauduin, Claire" uniqKey="Bernede Bauduin C" first="Claire" last="Bernède-Bauduin">Claire Bernède-Bauduin</name></author><author><name sortKey="Pepin, Sophie" sort="Pepin, Sophie" uniqKey="Pepin S" first="Sophie" last="Pépin">Sophie Pépin</name></author><author><name sortKey="Leroy, Michel" sort="Leroy, Michel" uniqKey="Leroy M" first="Michel" last="Leroy">Michel Leroy</name></author><author><name sortKey="Boelle, Pierre Yves" sort="Boelle, Pierre Yves" uniqKey="Boelle P" first="Pierre-Yves" last="Boëlle">Pierre-Yves Boëlle</name></author><author><name sortKey="Watier, Laurence" sort="Watier, Laurence" uniqKey="Watier L" first="Laurence" last="Watier">Laurence Watier</name></author><author><name sortKey="Guillemot, Didier" sort="Guillemot, Didier" uniqKey="Guillemot D" first="Didier" last="Guillemot">Didier Guillemot</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2009">2009</date><idno type="RBID">pubmed:19492093</idno><idno type="pmid">19492093</idno><idno type="doi">10.1371/journal.pmed.1000084</idno><idno type="pmc">PMC2683932</idno><idno type="wicri:Area/Main/Corpus">000491</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000491</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Significant reduction of antibiotic use in the community after a nationwide campaign in France, 2002-2007.</title><author><name sortKey="Sabuncu, Elifsu" sort="Sabuncu, Elifsu" uniqKey="Sabuncu E" first="Elifsu" last="Sabuncu">Elifsu Sabuncu</name><affiliation><nlm:affiliation>INSERM, U657, Paris, France.</nlm:affiliation></affiliation></author><author><name sortKey="David, Julie" sort="David, Julie" uniqKey="David J" first="Julie" last="David">Julie David</name></author><author><name sortKey="Bernede Bauduin, Claire" sort="Bernede Bauduin, Claire" uniqKey="Bernede Bauduin C" first="Claire" last="Bernède-Bauduin">Claire Bernède-Bauduin</name></author><author><name sortKey="Pepin, Sophie" sort="Pepin, Sophie" uniqKey="Pepin S" first="Sophie" last="Pépin">Sophie Pépin</name></author><author><name sortKey="Leroy, Michel" sort="Leroy, Michel" uniqKey="Leroy M" first="Michel" last="Leroy">Michel Leroy</name></author><author><name sortKey="Boelle, Pierre Yves" sort="Boelle, Pierre Yves" uniqKey="Boelle P" first="Pierre-Yves" last="Boëlle">Pierre-Yves Boëlle</name></author><author><name sortKey="Watier, Laurence" sort="Watier, Laurence" uniqKey="Watier L" first="Laurence" last="Watier">Laurence Watier</name></author><author><name sortKey="Guillemot, Didier" sort="Guillemot, Didier" uniqKey="Guillemot D" first="Didier" last="Guillemot">Didier Guillemot</name></author></analytic><series><title level="j">PLoS medicine</title><idno type="eISSN">1549-1676</idno><imprint><date when="2009" type="published">2009</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adolescent (MeSH)</term><term>Age Distribution (MeSH)</term><term>Anti-Bacterial Agents (therapeutic use)</term><term>Child (MeSH)</term><term>Drug Prescriptions (statistics & numerical data)</term><term>Drug Resistance, Bacterial (MeSH)</term><term>Drug Utilization (trends)</term><term>France (MeSH)</term><term>Health Policy (MeSH)</term><term>Humans (MeSH)</term><term>Influenza, Human (drug therapy)</term><term>Practice Patterns, Physicians' (trends)</term><term>Program Evaluation (MeSH)</term><term>Public Health (MeSH)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Anti-Bacterial Agents</term></keywords><keywords scheme="MESH" type="geographic" xml:lang="en"><term>France</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="statistics & numerical data" xml:lang="en"><term>Drug Prescriptions</term></keywords><keywords scheme="MESH" qualifier="trends" xml:lang="en"><term>Drug Utilization</term><term>Practice Patterns, Physicians'</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adolescent</term><term>Age Distribution</term><term>Child</term><term>Drug Resistance, Bacterial</term><term>Health Policy</term><term>Humans</term><term>Program Evaluation</term><term>Public Health</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p><b>BACKGROUND</b></p><p>Overuse of antibiotics is the main force driving the emergence and dissemination of bacterial resistance in the community. France consumes more antibiotics and has the highest rate of beta-lactam resistance in Streptococcus pneumoniae than any other European country. In 2001, the government initiated "Keep Antibiotics Working"; the program's main component was a campaign entitled "Les antibiotiques c'est pas automatique" ("Antibiotics are not automatic") launched in 2002. We report the evaluation of this campaign by analyzing the evolution of outpatient antibiotic use in France 2000-2007, according to therapeutic class and geographic and age-group patterns.</p></div><div type="abstract" xml:lang="en"><p><b>METHODS AND FINDINGS</b></p><p>This evaluation is based on 2000-2007 data, including 453,407,458 individual reimbursement data records and incidence of flu-like syndromes (FLSs). Data were obtained from the computerized French National Health Insurance database and provided by the French Sentinel Network. As compared to the preintervention period (2000-2002), the total number of antibiotic prescriptions per 100 inhabitants, adjusted for FLS frequency during the winter season, changed by -26.5% (95% confidence interval [CI] -33.5% to -19.6%) over 5 years. The decline occurred in all 22 regions of France and affected all antibiotic therapeutic classes except quinolones. The greatest decrease, -35.8% (95% CI -48.3% to -23.2%), was observed among young children aged 6-15 years. A significant change of -45% in the relationship between the incidence of flu-like syndromes and antibiotic prescriptions was observed.</p></div><div type="abstract" xml:lang="en"><p><b>CONCLUSIONS</b></p><p>The French national campaign was associated with a marked reduction of unnecessary antibiotic prescriptions, particularly in children. This study provides a useful method for assessing public-health strategies designed to reduce antibiotic use.</p></div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">19492093</PMID><DateCompleted><Year>2009</Year><Month>07</Month><Day>23</Day></DateCompleted><DateRevised><Year>2019</Year><Month>12</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1549-1676</ISSN><JournalIssue CitedMedium="Internet"><Volume>6</Volume><Issue>6</Issue><PubDate><Year>2009</Year><Month>Jun</Month><Day>02</Day></PubDate></JournalIssue><Title>PLoS medicine</Title><ISOAbbreviation>PLoS Med.</ISOAbbreviation></Journal><ArticleTitle>Significant reduction of antibiotic use in the community after a nationwide campaign in France, 2002-2007.</ArticleTitle><Pagination><MedlinePgn>e1000084</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pmed.1000084</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Overuse of antibiotics is the main force driving the emergence and dissemination of bacterial resistance in the community. France consumes more antibiotics and has the highest rate of beta-lactam resistance in Streptococcus pneumoniae than any other European country. In 2001, the government initiated "Keep Antibiotics Working"; the program's main component was a campaign entitled "Les antibiotiques c'est pas automatique" ("Antibiotics are not automatic") launched in 2002. We report the evaluation of this campaign by analyzing the evolution of outpatient antibiotic use in France 2000-2007, according to therapeutic class and geographic and age-group patterns.</AbstractText><AbstractText Label="METHODS AND FINDINGS" NlmCategory="RESULTS">This evaluation is based on 2000-2007 data, including 453,407,458 individual reimbursement data records and incidence of flu-like syndromes (FLSs). Data were obtained from the computerized French National Health Insurance database and provided by the French Sentinel Network. As compared to the preintervention period (2000-2002), the total number of antibiotic prescriptions per 100 inhabitants, adjusted for FLS frequency during the winter season, changed by -26.5% (95% confidence interval [CI] -33.5% to -19.6%) over 5 years. The decline occurred in all 22 regions of France and affected all antibiotic therapeutic classes except quinolones. The greatest decrease, -35.8% (95% CI -48.3% to -23.2%), was observed among young children aged 6-15 years. A significant change of -45% in the relationship between the incidence of flu-like syndromes and antibiotic prescriptions was observed.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The French national campaign was associated with a marked reduction of unnecessary antibiotic prescriptions, particularly in children. This study provides a useful method for assessing public-health strategies designed to reduce antibiotic use.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sabuncu</LastName><ForeName>Elifsu</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>INSERM, U657, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>David</LastName><ForeName>Julie</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Bernède-Bauduin</LastName><ForeName>Claire</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Pépin</LastName><ForeName>Sophie</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Leroy</LastName><ForeName>Michel</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Boëlle</LastName><ForeName>Pierre-Yves</ForeName><Initials>PY</Initials></Author><Author ValidYN="Y"><LastName>Watier</LastName><ForeName>Laurence</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Guillemot</LastName><ForeName>Didier</ForeName><Initials>D</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D023362">Evaluation Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2009</Year><Month>06</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS Med</MedlineTA><NlmUniqueID>101231360</NlmUniqueID><ISSNLinking>1549-1277</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000900">Anti-Bacterial Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>PLoS Med. 2009 Jun 2;6(6):e1000080</RefSource><PMID Version="1">19492081</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017677" MajorTopicYN="N">Age Distribution</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000900" MajorTopicYN="N">Anti-Bacterial Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011307" MajorTopicYN="N">Drug Prescriptions</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics & numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D024881" MajorTopicYN="Y">Drug Resistance, Bacterial</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004363" MajorTopicYN="N">Drug Utilization</DescriptorName><QualifierName UI="Q000639" MajorTopicYN="Y">trends</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005602" MajorTopicYN="N" Type="Geographic">France</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006291" MajorTopicYN="N">Health Policy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010818" MajorTopicYN="N">Practice Patterns, Physicians'</DescriptorName><QualifierName UI="Q000639" MajorTopicYN="Y">trends</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015397" MajorTopicYN="N">Program Evaluation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011634" MajorTopicYN="N">Public Health</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2008</Year><Month>10</Month><Day>08</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2009</Year><Month>04</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>6</Month><Day>4</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>6</Month><Day>6</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>7</Month><Day>25</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19492093</ArticleId><ArticleId IdType="doi">10.1371/journal.pmed.1000084</ArticleId><ArticleId IdType="pmc">PMC2683932</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>N Engl J Med. 1997 Oct 2;337(14):970-6</Citation><ArticleIdList><ArticleId IdType="pubmed">9395430</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Intern Med. 1997 Aug 11-25;157(15):1709-18</Citation><ArticleIdList><ArticleId IdType="pubmed">9250232</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 1999 Apr 28;281(16):1512-9</Citation><ArticleIdList><ArticleId IdType="pubmed">10227321</ArticleId></ArticleIdList></Reference><Reference><Citation>Scand J Infect Dis. 1999;31(2):191-5</Citation><ArticleIdList><ArticleId IdType="pubmed">10447331</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 2004 Nov 24;292(20):2468-70</Citation><ArticleIdList><ArticleId IdType="pubmed">15562124</ArticleId></ArticleIdList></Reference><Reference><Citation>J Antimicrob Chemother. 2004 Dec;54(6):1116-21</Citation><ArticleIdList><ArticleId IdType="pubmed">15546973</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2005 Feb 12-18;365(9459):579-87</Citation><ArticleIdList><ArticleId IdType="pubmed">15708101</ArticleId></ArticleIdList></Reference><Reference><Citation>Emerg Infect Dis. 2005 Jun;11(6):912-20</Citation><ArticleIdList><ArticleId IdType="pubmed">15963287</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Infect Dis. 2005 Oct 1;41(7):930-8</Citation><ArticleIdList><ArticleId IdType="pubmed">16142656</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Epidemiol. 2006 Jan 15;163(2):160-70</Citation><ArticleIdList><ArticleId IdType="pubmed">16319292</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Clin Pharmacol. 2006 May;62(5):373-9</Citation><ArticleIdList><ArticleId IdType="pubmed">16568344</ArticleId></ArticleIdList></Reference><Reference><Citation>J Antimicrob Chemother. 2006 Oct;58(4):830-9</Citation><ArticleIdList><ArticleId IdType="pubmed">16921182</ArticleId></ArticleIdList></Reference><Reference><Citation>Health Promot Int. 2007 Mar;22(1):53-64</Citation><ArticleIdList><ArticleId IdType="pubmed">17046966</ArticleId></ArticleIdList></Reference><Reference><Citation>J Antimicrob Chemother. 2007 Mar;59(3):537-43</Citation><ArticleIdList><ArticleId IdType="pubmed">17283035</ArticleId></ArticleIdList></Reference><Reference><Citation>Euro Surveill. 2007 Mar;12(3):E070315.3</Citation><ArticleIdList><ArticleId IdType="pubmed">17439787</ArticleId></ArticleIdList></Reference><Reference><Citation>J Antimicrob Chemother. 2007 Aug;60 Suppl 1:i15-26</Citation><ArticleIdList><ArticleId IdType="pubmed">17656377</ArticleId></ArticleIdList></Reference><Reference><Citation>BMJ. 2007 Nov 10;335(7627):982</Citation><ArticleIdList><ArticleId IdType="pubmed">17947744</ArticleId></ArticleIdList></Reference><Reference><Citation>Euro Surveill. 2007 Oct;12(10):E071011.1</Citation><ArticleIdList><ArticleId IdType="pubmed">17997918</ArticleId></ArticleIdList></Reference><Reference><Citation>Pediatrics. 2008 Jan;121(1):e15-23</Citation><ArticleIdList><ArticleId IdType="pubmed">18166533</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Infect Dis. 2008 Jan 15;46(2):174-82</Citation><ArticleIdList><ArticleId IdType="pubmed">18171247</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Infect Dis. 2008 Feb;8(2):125-32</Citation><ArticleIdList><ArticleId IdType="pubmed">18222163</ArticleId></ArticleIdList></Reference><Reference><Citation>BMJ. 2008 Jun 7;336(7656):1266-7</Citation><ArticleIdList><ArticleId IdType="pubmed">18535047</ArticleId></ArticleIdList></Reference><Reference><Citation>Epidemiol Infect. 2008 Sep;136(9):1217-24</Citation><ArticleIdList><ArticleId IdType="pubmed">18047748</ArticleId></ArticleIdList></Reference><Reference><Citation>Emerg Infect Dis. 2008 Nov;14(11):1722-30</Citation><ArticleIdList><ArticleId IdType="pubmed">18976555</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 1998 Mar 18;279(11):875-7</Citation><ArticleIdList><ArticleId IdType="pubmed">9516004</ArticleId></ArticleIdList></Reference><Reference><Citation>Pediatrics. 2001 Jan;107(1):E6</Citation><ArticleIdList><ArticleId IdType="pubmed">11134470</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Infect Dis. 2001 Apr 1;32(7):1044-54</Citation><ArticleIdList><ArticleId IdType="pubmed">11264033</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2001 Jun 9;357(9271):1851-3</Citation><ArticleIdList><ArticleId IdType="pubmed">11410197</ArticleId></ArticleIdList></Reference><Reference><Citation>Pediatrics. 2001 Jul;108(1):1-7</Citation><ArticleIdList><ArticleId IdType="pubmed">11433046</ArticleId></ArticleIdList></Reference><Reference><Citation>Pediatrics. 2001 Sep;108(3):575-83</Citation><ArticleIdList><ArticleId IdType="pubmed">11533321</ArticleId></ArticleIdList></Reference><Reference><Citation>Pediatrics. 2001 Sep;108(3):591-6</Citation><ArticleIdList><ArticleId IdType="pubmed">11533323</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Infect Dis. 2002 Jun 15;34(12):1558-63</Citation><ArticleIdList><ArticleId IdType="pubmed">12032889</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 2002 Jun 19;287(23):3096-102</Citation><ArticleIdList><ArticleId IdType="pubmed">12069672</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 2002 Jun 19;287(23):3103-9</Citation><ArticleIdList><ArticleId IdType="pubmed">12069673</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Intern Med. 2003 Apr 1;138(7):525-33</Citation><ArticleIdList><ArticleId IdType="pubmed">12667022</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Med. 2003 Apr;9(4):424-30</Citation><ArticleIdList><ArticleId IdType="pubmed">12627227</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Pediatr Adolesc Med. 2004 Jun;158(6):577-83</Citation><ArticleIdList><ArticleId IdType="pubmed">15184222</ArticleId></ArticleIdList></Reference><Reference><Citation>J Antimicrob Chemother. 2004 Aug;54(2):524-8</Citation><ArticleIdList><ArticleId IdType="pubmed">15243024</ArticleId></ArticleIdList></Reference><Reference><Citation>Emerg Infect Dis. 2004 Jul;10(7):1250-7</Citation><ArticleIdList><ArticleId IdType="pubmed">15324545</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 1983 Oct 7;250(13):1728-32</Citation><ArticleIdList><ArticleId IdType="pubmed">6350633</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Public Health. 1986 Nov;76(11):1289-92</Citation><ArticleIdList><ArticleId IdType="pubmed">3766824</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 1995 Jan 18;273(3):214-9</Citation><ArticleIdList><ArticleId IdType="pubmed">7807660</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/GrippeFranceV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000491 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 000491 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= GrippeFranceV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= pubmed:19492093
|texte= Significant reduction of antibiotic use in the community after a nationwide campaign in France, 2002-2007.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Corpus/RBID.i -Sk "pubmed:19492093" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a GrippeFranceV1
| This area was generated with Dilib version V0.6.35. |  |